Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months

CoinMarketCap05-13

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions. Biotech stocks, especially of smaller ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435377591?lang=en_US&edition=fundamental","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/895ab18e8a8b4f9886c74ba5a140116c.jpeg","is_english":true,"pubTime":"2024-05-13 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435377591","market":"us","top_or_hot":-1,"title":"Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months","media":"CoinMarketCap","content":"<div>\n<p>Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.\n\nBiotech stocks, especially of smaller ...</p>\n\n<a href=\"https://coinmarketcap.com/community/articles/664237b84463b457e78d80a2/\">Source Link</a>\n\n</div>\n","source":"coinmarketcap_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-13 23:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://coinmarketcap.com/community/articles/664237b84463b457e78d80a2/><strong>CoinMarketCap</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.\n\nBiotech stocks, especially of smaller ...</p>\n\n<a href=\"https://coinmarketcap.com/community/articles/664237b84463b457e78d80a2/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TQQQ","symbol_name":"纳指三倍做多ETF","start_time":0,"source_url":"https://coinmarketcap.com/community/articles/664237b84463b457e78d80a2/","article_id":"2435377591","we_media_id":null,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/895ab18e8a8b4f9886c74ba5a140116c.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435377591","pubTimestamp":1715615662,"sourceInfo":{"source_id":"coinmarketcap_highlight","name":"CoinMarketCap"},"weMediaInfo":null,"summary":"Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions. Biotech stocks, especially of s","collect":0,"end_time":0,"defaultTopTitle":"coinmarketcap.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TQQQ":"纳指三倍做多ETF","IBRX":"ImmunityBio, Inc.","PFE":"辉瑞","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4007":"制药","BCG":"Binah Capital Group Inc","BK4554":"元宇宙及AR概念","QQQ":"纳指100ETF","BK4567":"ESG概念","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4532":"文艺复兴科技持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4121":"生命科学工具和服务","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","QID":"纳指两倍做空ETF","NVDA":"英伟达","SGEN":"Seagen","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4549":"软银资本持仓","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BIO":"Bio Rad实验室","SEER":"Seer, Inc.","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4550":"红杉资本持仓","LEGN":"传奇生物","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4534":"瑞士信贷持仓"},"translate_title":"在生物技术陷阱中，这只股票在过去3个月的表现超过了NVDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCG":1,"LEGN":1,"IBRX":1,"NVDA":1,"PFE":1,"SEER":1,"SGEN":1,"BIO":1,".IXIC":0.61,"TQQQ":0.6,"SQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.\n\nBiotech stocks, especially of smaller companies, are notoriously risky investment exposures. Because their bread and butter is drug development, its complexity cannot be easily accounted for. \nAlthough the Center for Drug Evaluation and Research (CDER) approved 86% of new molecular entities (NMEs) in 2022, they must pass multiple clinical phase trials. According to a study from Biotechnology Industry Organization (BIO) Industry Analysis and BioMedTracker (BMT), the FDA, on average, approved nearly 9% of Phase I in the early 2000s. \nAdditionally, the probability of success (PoS) shifts depending on the use of biomarkers in patient selection, according to the 2019 Biostatistics study. During those trying times, biotech companies must carefully balance their limited budgets until a drug pipeline hits the jackpot, as recently happened with Legend Biotech’s (NASDAQ: LEGN) CARVYKTI for bone marrow cancer.\nThe added complexity of biotech investing is financial. By the time Pfizer (NYSE: PFE) paid $43 billion for oncology firm Seagen (SGEN) in December 2023, the stock had gained 70% value on a yearly basis, from $124 to $212 per share. This indicates that behind-the-scenes dealings can cut short potential upside for retail investors.\nGiven these factors, what is ImmunityBio (NASDAQ: IBRX) ‘s status as a prospective biostock candidate?\nImmunityBio’s Claim to Fame\nFounded in 2014 in San Diego, California, ImmunityBio is a clinical-stage biotech firm. As its name suggests, it specializes in immunity-enhancing therapies and vaccines. In particular, the FDA approved ImmunityBio’s Anktiva this April. The drug is designated an FDA Breakthrough Therapy, as it activates the body’s T-cell immune system to attack tumor cells.\nIn combination with ImmunityBio’s Bacillus Calmette-Guérin (BCG) vaccine, Anktiva (N-803) is set to treat non-muscle invasive bladder cancer (NMIBC) from mid-May. For investors, bladder cancer is fairly common, at an average rate of 18.2 per 100,000, with 75-80% of newly diagnosed cases classified as NMBIC.\nIn 2024, Anktiva’s addressable market in the US is 83,190, as estimated new cases by the Surveillance, Epidemiology, and End Results (SEER) program under the National Institutes of Health (NIH). Of course, this doesn’t account for cases in which life expectancy varies according to stage. For example, stage 0 has a 98% five-year survival rate, while stage III bladder cancer has a 46% five-year survival rate.\nThe new drug’s recommended dosage is once per week for six weeks, with a potential follow-up after three months. Anktiva’s pricing strategy is set at around $35,800 per dose, potentially generating around $1.1 million in revenue, including course and maintenance. \n\n\nJoin our Telegram group and never miss a breaking story.\n\n\nImmunityBio’s Financials\nOn May 9th, ImmunityBio delivered its Q1 2024 earnings. Typical of smaller biotech startups, the firm reported a $134.1 million net loss, substantially higher than the $116.6 million net loss in the year-ago quarter. In share terms, this was a $0.20 net loss per common share (basic and diluted).\nHowever, operating expense losses decreased from $111.9 million to $95.2 million during the period. ImmunityBio left the quarter with $133.3 million in cash, cash equivalents, and restricted cash ($334k). \nThe company’s liabilities remained flat at $1.091 billion from the year-ago quarter. This puts the debt-to-equity ratio at a high negative 1.161, confirming that the company has more debt than assets. However, this is not that surprising for the capital-intensive biotech sector.\nAgainst the industry average of 24.83, ImmunityBio’s price-to-earnings (PE) ratio was -8.2 in 2023 and estimated -10.83 for 2024, per Nasdaq data. With the rollout of Anktiva and BCG, the P/E growth forecast in 2024 is 24.75. The latter PEG value is determined by dividing the P/E ratio by the expected future earnings growth rate.\nImmunityBio’s Price Moves and Forecast\nOver a one-year period, IBRX stock is up 165%, or 62.8% year-to-date, firmly leaving the penny stock territory in March. From the 52-week low of $1.25, IBRX shares are now 550% up at $8.12 per share.\nHowever, this is still 23% lower than the 52-week high of $10.53, suggesting some room for growth ahead of the Anktiva launch. Nasdaq’s aggregated forecast data suggests an average price target twelve months ahead of $6 per share. WSJ’s average price target is more optimistic at $7.50 per share. \nIs your investment exposure typically short-term or long-term? Let us know in the comments below.\nDisclaimer: The author does not hold or have a position in any securities discussed in the article.\nThe post Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months appeared first on Tokenist.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435377591"}